← Back to headlines
NRx Pharmaceuticals Files 10-K, Highlights Operational Progress and Q4 Earnings
NRx Pharmaceuticals announced its Q4 GAAP EPS of -$1.34 and revenue of $1.23 million, with further details highlighted during its earnings call, and has now filed its 2025 Form 10-K, emphasizing operational progress.
24 Mar, 15:55 — 24 Mar, 15:55
Related Stories
Philippines Health Secretary Herbosa calls expired medicine complaints a 'demolition job'
just now
PhilHealth eyes accreditation of pediatric neurologists for autism care
just now
WHO Receives Assurances from Israel on Beirut Hospitals
9m ago
Scientists Discover Enhanced Anti-Inflammatory Properties in Spice Combinations
12m ago